Marketing Mid-Tier Pharmaceutical Brands
Winning Resources for near-Blockbusters
| Publication Date | May 2006 |
|---|---|
| Publisher | Cutting Edge Information |
| Product Type | Report |
| Pages | 181 |
| ISBN Number | not applicable |
| Product Code | CUT00033 |
Summary
The following recommendations and conclusions were among Cutting Edge Information's top study findings:
- Mid-level drugs thrive in underserved markets and, therefore, must prepare for inevitable competition and generic entrants
Some of the most successful mid-level brands have branded themselves in markets where few competitors exist or have done poor jobs of commercializing their drugs. While pharmaceutical and biotechnology companies can capitalize on the opportunities these markets present, this situation leave many mid-level brands vulnerable to competitive threats, especially generic drugs. With relatively low resource to draw upon, mid-level drugs are susceptible to losing their market share rapidly, even prior to patent expiration...
- Promotional infrastructures limit mid-level brands from becoming blockbuster sellers.
An underdeveloped promotional organization and limited commercialization resources hold brands back at launch. For both European and US commercialized products, companies struggle to institute favorable promotional infrastructures for their products. Brands suffer most at launch from companies' weak presence and lack of experience. Of the European and US brands surveyed in this report, more than half had an average or unfavorable promotional infrastructure...
- Mid-level drugs must optimize their budgets and headcounts by consistently shifting resources between major functions
It is not uncommon to find mid-level brands shifting resources between support functions throughout the development process. Although none of the global-level brands neglected any major support functions, many re-prioritized their allocations at each development stage to focus on different goals...
- Balance brand priorities to commercialize mid-level drugs in Europe
Brand teams commercializing products with mid-level revenue expectations balance their investments to address key challenges, and they often sacrifice one avenue of resource allocation for another. Each of the mid-level brand teams that market drugs in Europe received conservative investments either in marketing spending or staffing throughout development. The brand teams managing these drugs made difficult resource decisions as they backed different approaches to launch...
- Intelligent commercialization choices lead to blockbuster-level aspirations for mid-level products, while mislaid resources can enormously hinder potential sales.
Mid-level brands tended to face uncertainty at launch. In their total expenditures and mix of key marketing expenditures, the group of six brands in this chapter reflects this uncertainty as many companies wait until Phase III to heavily dedicate resources...
Content
- Executive Summary
- Figure E.1: Mirroring Niche Allocations Early and Blockbuster Allocations Late
- Figure E.2: Study Context: Therapeutic Areas
- Global Resource Allocation
- Figure 1.1 Mid-Level Brand Expenditures and Sales
- Table 1.1: Mid-Level Brand Table
- Figure 1.2: Mirroring Niche Allocations Early and Blockbuster Allocations Late
- Figure 1.3: Mid-Level Brands' Staffing Mirrors Niche Brands' Staffing
- throughout Early Development
- Figure 1.4: Total Global Spending
- Figure 1.5: Total Global Staffing
- Figure 1.6: Global Brand Activities Spending
- Figure 1.7: Global Brand Activities Staffing
- Figure 1.8: Global Market Research Spending
- Figure 1.9: Global Market Research Staffing
- Figure 1.10: Global Thought Leader Development Spending
- Figure 1.11: Global Thought Leader Development Staffing
- Figure 1.12: Global Advertising Spending
- Figure 1.13: Global Advertising Staffing
- Brand
- Table 1.2: Brand 1 Spending
- Figure 1.14: Brand 1: Global Spending Allocation
- Table 1.3: Brand 1 Staffing Table
- Figure 1.15: Brand 1: Global Staffing Allocation
- Figure 1.16: Brand 1: Launch Context
- Brand
- Table 1.4: Brand 2 Spending
- Figure 1.17: Brand 2: Global Spending Allocation
- Table 1.5: Brand 2 Staffing
- Figure 1.18: Brand 2: Staffing Allocation
- Figure 1.19: Brand 2: Launch Context
- Brand
- Table 1.6: Brand 3 Spending
- Figure 1.20: Brand 3: Global Spending Allocation
- Table 1.7: Brand 3 Staffing
- Figure 1.21: Brand 3: Staffing Allocation
- Figure 1.22: Brand 3: Launch Context
- Brand
- Table 1.8: Brand 4 Spending
- Figure 1.23: Brand 4: Global Spending Allocation
- Table 1.9: Brand 4 Staffing
- Figure 1.24: Brand 4: Global Staffing Allocation
- Figure 1.25: Brand 4: Launch Context
- Brand
- Table 1.10: Brand 5 Spending Table
- Figure 1.26: Brand 5: Global Spending Allocation
- Table 1.11: Brand 5 Staffing Table
- Figure 1.27: Brand 5: Global Staffing Allocation
- Figure 1.28: Brand 5: Launch Context
- European Marketing
- Figure 2.1: European Marketing Mix
- Table 2.1: European Brand Table
- Figure 2.2: European Total Spending
- Figure 2.3: European Total Staffing
- Figure 2.4: European Brand Activities Spending
- Figure 2.5: European Brand Activities Staffing
- Figure 2.6: European Market Research Spending
- Figure 2.7: European Market Research Staffing
- Figure 2.8: European Thought Leader Development Spending
- Figure 2.9: Mid-Level Brand Thought Leader Development Staffing
- Figure 2.10: Mid-Level Brand Advertising Spending
- Figure 2.11: Mid-Level Brand Advertising Staffing
- Figure 2.12: European Brands' Average Marketing Spending as % of European Peak
- Annual Sales (by Resource Category)
- Figure 2.13: Mid-Level Brands' Average Peak Marketing Staffing (by Resource
- Category)
- Figure 2.14: European Brands' Total Marketing Spending (as % of European Peak
- Annual Sales)
- Figure 2.15: European Brands' Peak Total Marketing Staffing
- Figure 2.16: European Brands' Brand Activities Spending (as % of European Peak
- Annual Sales)
- Figure 2.17: European Brands' Peak Brand Activities Staffing
- Figure 2.18: European Brands' Market Research Spending (as % of European
- Peak Annual Sales)
- Figure 2.19: European Brands' Peak Market Research Staffing
- Figure 2.20: European Brands' Thought Leader Development Spending (as % of
- European Peak Annual Sales)
- Figure 2.21: European Brands' Peak Thought Leader Development Staffing
- Figure 2.22: European Brands' Advertising Spending (as % of European Peak
- Annual Sales)
- Figure 2.23: European Brands' Peak Advertising Staffing
- Brand
- Table 2.2: Brand 6 Spending
- Figure 2.25: Brand 6: Budget Allocation (Early-Stage)
- Figure 2.24: Brand 6: Budget Allocation
- Table 2.3: Brand 6 Staffing Table
- Figure 2.26: Brand 6: Staffing Allocation
- Figure 2.27: Brand 6: Launch Context
- Brand
- Table 2.4: Brand 7 Spending
- Figure 2.29: Brand 7: Budget Allocation (Early-Stage)
- Figure 2.28: Brand 7: Budget Allocation
- Table 2.5: Brand 7 Staffing
- Figure 2.30: Brand 7: Staffing Allocation
- Figure 2.31: Brand 7: Launch Context
- Brand
- Table 2.6: Brand 8 Spending
- Figure 2.33: Brand 6: Budget Allocation (Early-Stage)
- Figure 2.32: Brand 8: Budget Allocation
- Table 2.7: Brand 8 Staffing
- Figure 2.34: Brand 8: Staffing Allocation
- Figure 2.35: Brand 8: Launch Context
- Brand
- Table 2.8: Brand 9 Spending
- Figure 2.37: Brand 6: Budget Allocation (Early-Stage)
- Figure 2.36: Brand 9: Budget Allocation
- Table 2.9: Brand 9 Staffing
- Figure 2.38: Brand 9: Staffing Allocation
- Figure 2.39: Brand 9: Launch Context
- US Marketing
- Table 3.1: US Brand Table
- Figure 3.1: US Marketing Mix
- Figure 3.2: US Total Spending
- Figure 3.3: US Total Staffing
- Figure 3.4: US Brand Activities Spending
- Figure 3.5: US Brand Activities Staffing
- Figure 3.6: US Market Research Spending
- Figure 3.7: US Market Research Staffing
- Figure 3.8: US Thought Leader Development Spending
- Figure 3.9: US Thought Leader Development Staffing
- Figure 3.10: US Advertising Spending
- Figure 3.11: US Advertising Staffing
- Brand
- Table 3.2: Brand 10 Spending
- Figure 3.13: Brand 10: Budget Allocation (Early-Stage)
- Figure 3.12: Brand 10: Budget Allocation
- Table 3.3: Brand 10 Staffing Table
- Figure 3.14: Brand 10: Staffing Allocation
- Figure 3.15: Brand 10: Launch Context
- Figure 3.16: Brand 10 Sales Investment vs. US Average
- Brand
- Table 3.4: Brand 11 Spending
- Figure 3.18: Brand 11: Budget Allocation (Early-Stage)
- Figure 3.17: Brand 11: Budget Allocation
- Table 3.5: Brand 11 Staffing Table
- Figure 3.19: Brand 11: Staffing Allocation
- Figure 3.20: Brand 11: Launch Context
- Figure 3.21: Brand 11 Sales Investment vs. US Average
- Brand
- Table 3.6: Brand 12 Spending
- Figure 3.23: Brand 12: Budget Allocation (Early-Stage)
- Figure 3.22: Brand 12: Budget Allocation
- Table 3.7: Brand 12 Staffing Table
- Figure 3.24: Brand 12: Staffing Allocation
- Figure 3.25: Brand 12: Launch Context
- Figure 3.26: Brand 12 Sales Investment vs. US Average
- Brand
- Table 3.8: Brand 13 Spending
- Figure 3.28: Brand 13: Budget Allocation (Early-Stage)
- Figure 3.27: Brand 13: Budget Allocation
- Table 3.9: Brand 13 Staffing Table
- Figure 3.29: Brand 13: Staffing Allocation
- Figure 3.30: Brand 13: Launch Context
- Figure 3.31: Brand 13 Sales Investment vs. US Average
- Brand
- Table 3.10: Brand 14 Spending
- Figure 3.33: Brand 14: Budget Allocation (Early-Stage)
- Figure 3.32: Brand 14: Budget Allocation
- Table 3.11: Brand 14 Staffing Table
- Figure 3.34: Brand 14: Staffing Allocation
- Figure 3.35: Brand 14: Launch Context
- Figure 3.36: Brand 14 Sales Investment vs. US Average
- Brand
- Table 3.12: Brand 15 Spending
- Figure 3.38: Brand 15: Budget Allocation (Early-Stage)
- Figure 3.37: Brand 15: Budget Allocation
- Table 3.13: Brand 15 Staffing Table
- Figure 3.39: Brand 15: Staffing Allocation
- Figure 3.40: Brand 15: Launch Context
- Figure 3.41: Brand 15: Sales Investment vs. US Average
About this Product
Delivery Details
PDF:Delivered by email within 12 to 24 hours of placing the order (Mon-Fri)
PRINT/CD-ROM:Despatched within 2 to 4 working days.
Related Products
Recently Viewed Products
Pharma & Healthcare
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Chemicals
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us
Resources
Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Meet Us
Jobs
Contact Us
Categories and Subcategories

















